The use of the monoclonal antibody Erenumab in patients with chronic migraine in real clinical experience

Patients with chronic migraine are characterized by frequent severe headache attacks, polypharmacy (painkillers), insufficient effect of preventive therapy, and a decrease in the quality of life. The aim of a prospective open-label study was the evaluation of the efficacy and tolerance of Erenumab (Irinex) in the treatment of patients with chronic migraine in real clinical practice.

Material and methods. 48 patients with chronic migraine were clinically and neurologically examined (35.5 [19; 56]; diagnosis was established according to the criteria of ICHD classification and diagnosis of migraine. Medical monitoring period was 3 months. Clinical and neurological testing and subcutaneous administration of Erenumab (Irinex) 70 mg were performed once a month during the whole period.

Results. Safety, good tolerance and an obvious significant clinical effect were noted when using Erenumab (Irinex) 70 mg. It led to a significant improvement in clinical score and the course of chronic migraine, the effectiveness of rapid relief of symptoms and significant reduction in the need for painkillers in most patients. The best results were found after 3 months of therapy.

1. Steiner T.J., Birbeck G.L., Jensen R.H., Katsarava Z., Stovner L.J., Martelleti P. Headache disorders are third cause of disability worldwide. J. Headache Pain. 2015;16:58. http://dx.doi:10.1186/s10194-015-0544-2

2. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–1602. http://dx.doi:10.1016/S01406736(16)31678-6

3. Tietjen G.E., Collins S.A. Hypercoagulability and migraine. Headache. 2018;58(1):173–183. http://dx.doi:10.1111/head.13044

4. Bakar N.A., Tanprawate S., Lambru G., Torkamani M., Jahanshahi M., Matharu M. Quality of life in primary headache disorders: A review. Cephalalgia. 2016;36(1):67–91. http://dx.doi:10.1177/0333102415580099

5. Filatova E.G., Osipova V.V., Tabeeva G.R., Parfenov V.A., Ekusheva E.V., Azimova Yu.E., et al. Diagnosis and treatment of migraine: Russian experts’ recommendations. Neurology, Neuropsychiatry, Psychosomatics 2020;12(4):4–14. (Russian). https://doi.org/10.14412/2074-2711-2020-4-4-14

6. Burch R.C., Buse D.C., Lipton R.B. Migraine: epidemiology, burden, and comorbidity. Neurol Clin. 2019;37(4):631–649. http://dx.doi:10.1016/j.ncl.2019.06.001

7. Naprienko M.V., Smekalkina L.V., Safonov M.I., Filatova E.G., Ekusheva E.V., Artemenko A.R., et al. Real-world migraine burden: clinical and economic aspects. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(1):31–37. https://doi.org/10.17116/jnevro201911901131

8. Rivera-Mancilla E., Villalón C.M., MaassenVanDenBrink A. CGRP inhibitors for migraine prophylaxis: a safety review. Expert Opin. Drug Saf. 2020;19(10):1237–1250. https://doi:10.108 0/14740338.2020.1811229

9. Edvinsson L. Role of CGRP in migraine. Handb Exp Pharmacol. 2019;255:121–30. https://doi.org/10.1007/164_2018_201

10. Mitsikostas D.D., Reuter U. Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies. Curr. Opin. Neurol. 2017;30(3):272–280. https://doi:10.1097/WCO.0000000000000438

11. Masoud A.T., Hasan M.T., Sayed A., Edward H.N., Amer A.M., Naga A.E., et al. Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): A network meta-analysis of randomized controlled trials. J. Neurol. Sci. 2021;427:117505. https://doi.org/10.1016/j.jns.2021.117505.

12. Deng H., Li G.-G., Nie H., Feng Y.-Y., Guo G.-Y., Guo W.-L. et al. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine — an updated systematic review and meta-analysis. BMC Neurol. 2020;20(1):57. https://doi:10.1186/s12883-02001633-3

13. Sacco S., Bendtsen L., Ashina M., Reuter U., Terwindt G., Mitsikostas D.D. et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J. Headache Pain. 2019;20(1):6. https://doi:10.1186/s10194-0180955-y.PMID: 30651064

14. Zhu C., Guan J., Xiao H., Luo W., Tong R. Erenumab safety and efficacy in migraine: A systematic review and meta-analysis of randomizedclinicaltrials.Medicine(Baltimore).2019;98(52):e18483. https://doi:10.1097/MD.0000000000018483

15. Bucklan J., Ahmed Z. CGRP antagonists for decreasing migraine frequency: new options, long overdue. Cleve Clin. J. Med. 2020;87(4):211–218. https://doi:10.3949/ccjm.87a.19048.

16. Chang C.L., Hsu S.Y.T. PLoS One. Development of chimeric and bifunctional antagonists for CLR/RAMP receptors. 2019;14(5):e0216996. https://doi:10.1371/journal.pone.0216996

17. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. https://doi:10.1177/0333102417738202

18. Buse D.C., Greisman J.D., Baigi K., Lipton R.B. Migraine progression: a systematic review. Headache. 2019;59(3):306–338. https://doi:10.1111/head.13459

19. Ashina M., Goadsby P.J., Reuter U., Silberstein S., Dodick D.W., Xue F. et al. Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur. J. Neurol. 2021;28(5):1716–1725. https://doi:10.1111/ene.14715

20. Raffaelli B., Kalantzis R., Mecklenburg J., Overeem L.H., Neeb L., Gendolla A., et al. Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxinA: a dual-center retrospective observational study. Fronties in Neurology. 2020;11:417. https://doi.org/10.3389/fneur.2020.00417

21. Tepper S., Ashina M., Reuter U., Brandes J.L., Doležil D., Silberstein S. et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebocontrolled phase 2 trial. Lancet Neurology. 2017;16(6):425–434. https://doi.org/10.1016/S1474-4422(17)30083-2

22. Lambru G., Hill B., Murphy M., Tylova I., Andreou A.P. A prospective real-world analysis of erenumab in refractory chronic migraine. The Journal of Headache and Pain. 2020;21(1):61. https://doi.org/10.1186/s10194-020-01127-0